Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

DSRB recommends continuation of Bextra study

March 1, 1999

C5a receptor antagonist with therapeutic potential in endotoxic shock, ARDS

Feb. 26, 1999

CytRx reaches midpoint in Flocor trial

Feb. 25, 1999

Spotlight on double and triple enzyme inhibitors for treating cardiovascular disease

Feb. 24, 1999

Tissue factor inhibition: another mechanism linked to the cardiovascular effects of resveratrol

Feb. 23, 1999

Trial results of rhVEGF165 in CAD disappointing

Feb. 23, 1999

AVI BioPharma presents data from preclinical study of Resten-NG in restenosis

Feb. 22, 1999

Renal protective effects of azelnidipine involve inhibition of AGE production

Feb. 22, 1999

Antihypertensive effects of bradykinin agonist FR-190997 evaluated in animals

Feb. 22, 1999

Novel antihypertensive drug candidate available for licensing from VUFB

Feb. 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...